Cytokinetics CYTK Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's proceeds from exercises of stock options and other stock issuances?
- Cytokinetics (CYTK) reported proceeds from exercises of stock options and other stock issuances of $11.35M in Q1 2026.
- How has Cytokinetics's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Cytokinetics's proceeds from exercises of stock options and other stock issuances increased by 48.3% year-over-year, from $7.65M to $11.35M.
- What is the long-term trend for Cytokinetics's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), Cytokinetics's proceeds from exercises of stock options and other stock issuances has grown at a 27.1% compound annual growth rate (CAGR), from $17.54M to $35.98M.